RHUMBLINE ADVISERS - CATABASIS PHARMACEUTICALS IN ownership

CATABASIS PHARMACEUTICALS IN's ticker is and the CUSIP is 14875P206. A total of 64 filers reported holding CATABASIS PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.

Quarter-by-quarter ownership
RHUMBLINE ADVISERS ownership history of CATABASIS PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2021$61,000
+35.6%
21,1430.0%0.00%
Q4 2020$45,000
-46.4%
21,143
+55.7%
0.00%
Q3 2020$84,000
-16.8%
13,580
-13.6%
0.00%
Q2 2020$101,00015,7150.00%
Other shareholders
CATABASIS PHARMACEUTICALS IN shareholders Q4 2020
NameSharesValueWeighting ↓
Eversept Partners, LP 522,042$1,117,1700.13%
XTX MARKETS LLC 26,041$56,0000.12%
Samsara BioCapital, LLC 300,000$642,0000.06%
Ikarian Capital, LLC 650,000$1,392,0000.06%
Opaleye Management Inc. 187,750$402,0000.05%
SABBY MANAGEMENT, LLC 108,026$231,0000.04%
Anson Funds Management LP 97,601$209,0000.04%
Virtu Financial LLC 83,221$178,0000.02%
GSA CAPITAL PARTNERS LLP 47,084$101,0000.02%
WEXFORD CAPITAL LP 19,512$42,0000.01%
View complete list of CATABASIS PHARMACEUTICALS IN shareholders